High cyclin B1 expression is associated with poor survival in breast cancer - PubMed (original) (raw)

High cyclin B1 expression is associated with poor survival in breast cancer

K Aaltonen et al. Br J Cancer. 2009.

Abstract

Cyclin B1 regulates the G(2)-M transition of the cell cycle. Cyclin B1 expression is higher in premalignant and malignant than normal breast lesions. Correlation of cyclin B1 expression with other histopathological variables and prognostic role in breast cancer are not fully understood. Traditionally used prognostic criteria identify large subset of patients to receive adjuvant chemotherapy and to be exposed to adverse effects. A reliable and simple method helping prognostic evaluation in breast cancer is needed. We analysed cyclin B1 expression on 1348 invasive breast cancers and studied correlations with other histopathological variables and survival. High cyclin B1 correlated with high tumour grade, large tumour size and positive nodal status, oestrogen and progesterone receptor negativity, positive HER2 and p53 status, young age at diagnosis, and high cyclin E, cyclin A and Ki67 expression. Among patients not given adjuvant chemotherapy high cyclin B1 was a strong predictor of shorter overall and metastasis-free survival (RR 3.74, P<0.0005 and RR 3.51, P<0.0005, respectively), and remained as an independent prognostic factor also in multivariate analysis (RR 1.80, P=0.04 and RR 2.31, P=0.02, respectively). This study suggests high cyclin B1 associates with aggressive phenotype and is an independent prognostic factor in breast cancer.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Kaplan–Meier curves showing metastasis-free and overall survival for cyclin B1 dichotomised at 5.6% (7th decile). (A) Metastasis-free survival among chemotherapy-naive patients (_n_=473). (B) Metastasis-free survival among patients having received adjuvant chemotherapy (_n_=323). (C) Overall survival among chemotherapy-naive patients (_n_=473). (D) Overall survival among patients having received adjuvant chemotherapy (_n_=473). Kaplan–Meier curves constructed and _P_-values counted comparing the subsets of cases using a log-rank test.

References

    1. Aaltonen K, Ahlin C, Amini RM, Salonen L, Fjällskog ML, Heikkilä P, Nevanlinna H, Blomqvist C (2006) Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer 94: 1697–1702 - PMC - PubMed
    1. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C (2007) Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51: 491–498 - PubMed
    1. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche Jr H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol 19: 1865–1878 - PubMed
    1. Bryant J, Fisher B, Gunduz N, Costantino JP, Emir B (1998) S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 51: 239–253 - PubMed
    1. Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, d′Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ, TRANSBIG Consortium (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183–1192 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources